Apellis Pharmaceuticals (NASDAQ: APLS) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Apellis Pharmaceuticals to related businesses based on the strength of its valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.
This table compares Apellis Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Apellis Pharmaceuticals Competitors||-13,384.94%||-54.87%||-26.30%|
This table compares Apellis Pharmaceuticals and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Apellis Pharmaceuticals||N/A||-$27.12 million||N/A|
|Apellis Pharmaceuticals Competitors||$638.71 million||$80.60 million||78.30|
Apellis Pharmaceuticals’ peers have higher revenue and earnings than Apellis Pharmaceuticals.
This is a summary of recent ratings and target prices for Apellis Pharmaceuticals and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Apellis Pharmaceuticals Competitors||176||848||1862||61||2.61|
Apellis Pharmaceuticals presently has a consensus price target of $27.00, indicating a potential upside of 40.85%. As a group, “Biopharmaceuticals” companies have a potential upside of 3.52%. Given Apellis Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Apellis Pharmaceuticals is more favorable than its peers.
Institutional & Insider Ownership
11.9% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 42.7% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 15.0% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Apellis Pharmaceuticals beats its peers on 6 of the 11 factors compared.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.